AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25363178 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin 100 mg PRN and hydration (control group)
Number of subjects: 96
Study 22538682 — intervention group
Group type: EXPERIMENTAL
Intervention: LigaSure
Number of subjects: 100
Study 22538682 — intervention group
Group type: COMPARATOR
Intervention: Conventional bipolar instruments
Number of subjects: 100
Study 20102995 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief counseling intervention delivered by a primary care physician
Number of subjects: 752
Study 18565217 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic methotrexate (MTX) - single dose intramuscular regimen (1 mg/kg)
Number of subjects: 0
Study 18565217 — intervention group
Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 0
Study 16087057 — intervention group
Group type: EXPERIMENTAL
Intervention: ACTH treatment (n = 26)
Number of subjects: 69
Study 16087057 — intervention group
Group type: COMPARATOR
Intervention: Oral steroid treatment (n = 18)
Number of subjects: 69
Study 16087057 — intervention group
Group type: COMPARATOR
Intervention: No treatment (n = 25)
Number of subjects: 69
Study 16087057 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose ACTH
Number of subjects: 69
Study 16087057 — intervention group
Group type: EXPERIMENTAL
Intervention: ACTH treatment
Number of subjects: 69
Study 11821278 — intervention group
Group type: EXPERIMENTAL
Intervention: Withdrawal of vaginal progesterone from the day of positive HCG (study group, n = 150)
Number of subjects: 303
Study 11821278 — intervention group
Group type: COMPARATOR
Intervention: Continued administration of vaginal progesterone for 3 weeks after positive HCG (control group, n = 153)
Number of subjects: 303
Study 10953944 — intervention group
Group type: EXPERIMENTAL
Intervention: Participation in the early intervention program (Infant Health and Development Program)
Number of subjects: 869
Study 10953944 — intervention group
Group type: COMPARATOR
Intervention: Service patterns at age 5
Number of subjects: 869
Study 9175992 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet A (12% protein)
Number of subjects: 55
Study 9175992 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet B (21% protein)
Number of subjects: 55
Study 1551495 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (500 mg)
Number of subjects: 9
Study 1551495 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 3929067 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemo-immunotherapy consisting of Tegafur, Adriamycin (ADM), Mitomycin C (MMC) and OK432
Number of subjects: 189
Study 3929067 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemo-immunotherapy
Number of subjects: 189
Study 3929067 — intervention group
Group type: EXPERIMENTAL
Intervention: Tegafur and ADM
Number of subjects: 189
Study 3929067 — intervention group
Group type: EXPERIMENTAL
Intervention: Tegafur alone
Number of subjects: 189
Study 3929067 — intervention group
Group type: EXPERIMENTAL
Intervention: Tegafur and MMC
Number of subjects: 189
Study 3929067 — intervention group
Group type: EXPERIMENTAL
Intervention: MMC during operation
Number of subjects: 189
Study 29450689 — intervention group
Group type: EXPERIMENTAL
Intervention: Home telemonitoring group (n=90)
Number of subjects: 181
Study 29450689 — intervention group
Group type: COMPARATOR
Intervention: Usual care group (n=91)
Number of subjects: 181
Study 26699690 — intervention group
Group type: EXPERIMENTAL
Intervention: General anaesthesia combined with thoracic epidural anaesthesia (TEA)
Number of subjects: 219
Study 26699690 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia
Number of subjects: 219
Study 26699690 — intervention group
Group type: EXPERIMENTAL
Intervention: General anaesthesia combined with infusion of 1 μg/kg dexmedetomidine
Number of subjects: 219
Study 24838844 — intervention group
Group type: EXPERIMENTAL
Intervention: Pathways to Freedom (PTF) DVD
Number of subjects: 140
Study 24838844 — intervention group
Group type: COMPARATOR
Intervention: Standard control DVD
Number of subjects: 140
Study 22805901 — intervention group
Group type: EXPERIMENTAL
Intervention: Information Technology‐Aided Program of Relapse Prevention in Schizophrenia (ITAREPS)
Number of subjects: 146
Study 22805901 — intervention group
Group type: EXPERIMENTAL
Intervention: ITAREPS Algorithm-Adherers (IAAs)
Number of subjects: 146
Study 22805901 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 146
Study 20087363 — intervention group
Group type: EXPERIMENTAL
Intervention: IV tissue plasminogen activator (tPA)
Number of subjects: 98
Study 20087363 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study 18765877 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 ml/kg Ringer lactate iv (Group B)
Number of subjects: 60
Study 18765877 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 ml/kg 4.5% hydroxyethylstarch (Hetastarch) iv (Group C)
Number of subjects: 60
Study 18765877 — intervention group
Group type: COMPARATOR
Intervention: 2 ml/kg Ringer lactate iv (Group A)
Number of subjects: 60
Study 15885641 — intervention group
Group type: EXPERIMENTAL
Intervention: Allergen inhalation
Number of subjects: 0
Study 15885641 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral glucocorticoid (prednisolone) therapy
Number of subjects: 0
Study 15885641 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 12665325 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate androgen deprivation (IAD) prior to conformal radiotherapy for 6 months
Number of subjects: 25
Study 12665325 — intervention group
Group type: COMPARATOR
Intervention: Deferred treatment strategy (DAD)
Number of subjects: 25
Study 10378632 — intervention group
Group type: EXPERIMENTAL
Intervention: Ifosfamide (5.0 g/m2) and epirubicin (80 mg/m2) with r‐metHuG‐CSF 5 microg/kg subcutaneously daily for 10 days (cohort A)
Number of subjects: 17
Study 10378632 — intervention group
Group type: EXPERIMENTAL
Intervention: Ifosfamide (5.0 g/m2) and epirubicin (80 mg/m2) with r‐metHuG‐CSF 5 microg/kg subcutaneously daily for 7 days (cohort B)
Number of subjects: 17
Study 9081356 — intervention group
Group type: EXPERIMENTAL
Intervention: High uPA tumours (uPA > 0.62 ng/mg protein)
Number of subjects: 688
Study 9081356 — intervention group
Group type: EXPERIMENTAL
Intervention: Not treated with systemic adjuvant therapy
Number of subjects: 688
Study 30230026 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse, dietician and physiotherapist group (n=27)
Number of subjects: 64
Study 30230026 — intervention group
Group type: COMPARATOR
Intervention: Nurse and dietician group (n=29)
Number of subjects: 64
Study 30230026 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment groups (n=56)
Number of subjects: 64
Study 30036082 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced SMBG frequency >1 test/day
Number of subjects: 175
Study 30036082 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced SMBG frequency ≤1 test/day
Number of subjects: 175
Study 30036082 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest quartile of SMBG frequency reduction (≥2.2 fewer tests/day)
Number of subjects: 175
Study 30036082 — intervention group
Group type: EXPERIMENTAL
Intervention: Lowest quartile of SMBG frequency reduction (≤0.4 fewer tests/day)
Number of subjects: 175
Study 27342507 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional dose of bortezomib
Number of subjects: 150
Study 27342507 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction dose of bortezomib
Number of subjects: 150
Study 24566903 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% diluted autologous serum (AS) eye drops
Number of subjects: 20
Study 24566903 — intervention group
Group type: COMPARATOR
Intervention: Preservative-free artificial tears (PFAT)
Number of subjects: 20
Study 22248153 — intervention group
Group type: EXPERIMENTAL
Intervention: Avanafil (50 mg, 100 mg, 200 mg)
Number of subjects: 646
Study 22248153 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 646
Study 17891409 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous paracetamol 1 g (Perfalgan)
Number of subjects: 76
Study 17891409 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% normal saline)
Number of subjects: 76
Study 15893524 — intervention group
Group type: EXPERIMENTAL
Intervention: Duple and triple classes of rhythm
Number of subjects: 0
Study 15893524 — intervention group
Group type: EXPERIMENTAL
Intervention: Metrical melodies
Number of subjects: 0
Study 15893524 — intervention group
Group type: COMPARATOR
Intervention: Non-metrical melodies
Number of subjects: 0
Study 14565658 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamidronate (PMD)
Number of subjects: 90
Study 14565658 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 90
Study 10800818 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-dose aprotinin
Number of subjects: 0
Study 10800818 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8764800 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% dorzolamide twice daily
Number of subjects: 293
Study 8764800 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 293
Study 8764800 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.7% dorzolamide twice daily
Number of subjects: 293
Study 8764800 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% pilocarpine four times daily
Number of subjects: 293
Study 8764800 — intervention group
Group type: COMPARATOR
Intervention: 2% pilocarpine
Number of subjects: 293
Study 1484739 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipenem-cilastatin (IC)
Number of subjects: 183
Study 1484739 — intervention group
Group type: COMPARATOR
Intervention: Ceftazidime-vancomycin (CV)
Number of subjects: 183
Study 1484739 — intervention group
Group type: COMPARATOR
Intervention: Ticarcillin-amikacin-vancomycin (TVA)
Number of subjects: 183
Study 3860335 — intervention group
Group type: EXPERIMENTAL
Intervention: Dental health education through home visits
Number of subjects: 0
Study 3860335 — intervention group
Group type: EXPERIMENTAL
Intervention: Dental health education through leaflets
Number of subjects: 0
Study 3860335 — intervention group
Group type: COMPARATOR
Intervention: Control group (no dental health education)
Number of subjects: 0
Study 3860335 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride supplements (for children of mothers who received personal advice)
Number of subjects: 0
Study 29782407 — intervention group
Group type: EXPERIMENTAL
Intervention: Heel group (gait training by active weight bearing on the paretic heel with auditory feedback)
Number of subjects: 31
Study 29782407 — intervention group
Group type: EXPERIMENTAL
Intervention: Forefoot group (gait training with auditory feedback from paretic metatarsals)
Number of subjects: 31
Study 29782407 — intervention group
Group type: COMPARATOR
Intervention: Control group (general gait intervention)
Number of subjects: 31
Study 26640036 — intervention group
Group type: EXPERIMENTAL
Intervention: S-1 plus leucovorin
Number of subjects: 145
Study 26640036 — intervention group
Group type: EXPERIMENTAL
Intervention: S-1 plus leucovorin and oxaliplatin
Number of subjects: 145
Study 26640036 — intervention group
Group type: COMPARATOR
Intervention: S-1 plus cisplatin
Number of subjects: 145
Study 24822154 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic septoplasty
Number of subjects: 50
Study 24822154 — intervention group
Group type: COMPARATOR
Intervention: Conventional septoplasty
Number of subjects: 50
Study 22473769 — intervention group
Group type: EXPERIMENTAL
Intervention: bapineuzumab
Number of subjects: 46
Study 22473769 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 46
Study 20739218 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib plus thalidomide and prednisone (VTP)
Number of subjects: 260
Study 20739218 — intervention group
Group type: COMPARATOR
Intervention: Bortezomib plus melphalan and prednisone (VMP)
Number of subjects: 260
Study 20739218 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib plus thalidomide (maintenance)
Number of subjects: 260
Study 20739218 — intervention group
Group type: COMPARATOR
Intervention: Bortezomib plus prednisone (maintenance)
Number of subjects: 260
Study 20739218 — intervention group
Group type: EXPERIMENTAL
Intervention: VTP
Number of subjects: 260
Study 20739218 — intervention group
Group type: COMPARATOR
Intervention: VMP
Number of subjects: 260
Study 17565633 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesalazine
Number of subjects: 64
Study 17565633 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesalazine + cholestyramine
Number of subjects: 64
Study 15945446 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term controlled treatment (DOTS)
Number of subjects: 66
Study 15945446 — intervention group
Group type: COMPARATOR
Intervention: Individual treatment regimens
Number of subjects: 66
Study 15945446 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadruple-combination therapy
Number of subjects: 66
Study 15945446 — intervention group
Group type: EXPERIMENTAL
Intervention: At least 5 antituberculous drugs
Number of subjects: 66
Study 12527599 — intervention group
Group type: EXPERIMENTAL
Intervention: AeroDose 90 mg
Number of subjects: 53
Study 12527599 — intervention group
Group type: EXPERIMENTAL
Intervention: AeroDose 30 mg
Number of subjects: 53
Study 12527599 — intervention group
Group type: EXPERIMENTAL
Intervention: AeroDose 60 mg
Number of subjects: 53
Study 12527599 — intervention group
Group type: COMPARATOR
Intervention: PARI LC PLUS 300 mg
Number of subjects: 53
Study 12527599 — intervention group
Group type: EXPERIMENTAL
Intervention: AeroDose (all doses)
Number of subjects: 53
Study 10473238 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone (2 g single dose)
Number of subjects: 200
Study 10473238 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin (500 mg i.v. every 6 h for 48 h)
Number of subjects: 200
Study 8888369 — intervention group
Group type: EXPERIMENTAL
Intervention: AMPT 1 g
Number of subjects: 10
Study 8888369 — intervention group
Group type: COMPARATOR
Intervention: Promethazine 50 mg (placebo)
Number of subjects: 10
Study 1676083 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional supplementation (1 kg milk-based formula per week for 2 years)
Number of subjects: 129
Study 1676083 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial stimulation (weekly play sessions at home with a community health aide)
Number of subjects: 129
Study 1676083 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined interventions (supplemented plus stimulated)
Number of subjects: 129
Study 1676083 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 129
Study 6603287 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin (1 mg iv over 24 hr, then 0.25 mg/day) and Propranolol (10 mg every 6 hr)
Number of subjects: 179
Study 6603287 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 179
Study 30725040 — intervention group
Group type: EXPERIMENTAL
Intervention: Case management approach
Number of subjects: 644
Study 30725040 — intervention group
Group type: COMPARATOR
Intervention: Usual care model (control)
Number of subjects: 644
Study 26891420 — intervention group
Group type: EXPERIMENTAL
Intervention: Tivantinib (360 mg/m² twice daily) plus biweekly cetuximab (500 mg/m²) and irinotecan (180 mg/m²)
Number of subjects: 117
Study 26891420 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus biweekly cetuximab (500 mg/m²) and irinotecan (180 mg/m²)
Number of subjects: 117
Study 24926781 — intervention group
Group type: COMPARATOR
Intervention: Baseline profile patterns of demographic, immunologic, and metabolic markers
Number of subjects: 356
Study 22182361 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Health Promotion (OHP) program implemented in nine schools since 2005
Number of subjects: 478
Study 22182361 — intervention group
Group type: COMPARATOR
Intervention: Schools without the OHP program
Number of subjects: 478
Study 22182361 — intervention group
Group type: EXPERIMENTAL
Intervention: OHP program in four schools
Number of subjects: 478
Study 20533444 — intervention group
Group type: EXPERIMENTAL
Intervention: ePTFE-covered stent
Number of subjects: 60
Study 20533444 — intervention group
Group type: COMPARATOR
Intervention: bare stent
Number of subjects: 60
Study 18794027 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 320 mg
Number of subjects: 16
Study 18794027 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 160 mg
Number of subjects: 16
Study 18794027 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 80 mg
Number of subjects: 16
Study 18794027 — intervention group
Group type: COMPARATOR
Intervention: Aspirin 0 mg
Number of subjects: 16
Study 16317380 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperdynamic left ventricular function (LVF) as assessed by echocardiography (ejection fraction >55%)
Number of subjects: 103
Study 16317380 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined in the abstract)
Number of subjects: 103
Study 12818934 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal opioid (1 micro g/kg sufentanil with 8 micro g/kg preservative-free morphine)
Number of subjects: 217
Study 12818934 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia alone (control)
Number of subjects: 217
Study 12818934 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal opioid
Number of subjects: 217
Study 10985008 — intervention group
Group type: EXPERIMENTAL
Intervention: Interdisciplinary prevention program (theater program)
Number of subjects: 301
Study 8791955 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg b.d. plus amoxycillin 1 g b.d.
Number of subjects: 231
Study 8791955 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg b.d. plus amoxycillin 1 g b.d.
Number of subjects: 231
Study 8791955 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 80 mg b.d. plus amoxycillin 1 g b.d.
Number of subjects: 231
Study 1536485 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g i.v. magnesium sulfate infused over 20 minutes
Number of subjects: 120
Study 1536485 — intervention group
Group type: COMPARATOR
Intervention: Control group (no magnesium)
Number of subjects: 120
Study 6142700 — intervention group
Group type: EXPERIMENTAL
Intervention: H2 receptor antagonist cimetidine in combination with H1 receptor antagonist chorpheniramine
Number of subjects: 16
Study 6142700 — intervention group
Group type: COMPARATOR
Intervention: Chlorpheniramine alone
Number of subjects: 16
Study 6142700 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 30878435 — intervention group
Group type: COMPARATOR
Intervention: CAC scores of 0
Number of subjects: 1205
Study 30878435 — intervention group
Group type: EXPERIMENTAL
Intervention: CAC scores >0 to 100
Number of subjects: 1205
Study 30878435 — intervention group
Group type: EXPERIMENTAL
Intervention: CAC scores >100 to 300
Number of subjects: 1205
Study 30878435 — intervention group
Group type: EXPERIMENTAL
Intervention: CAC scores >300
Number of subjects: 1205
Study 31166681 — intervention group
Group type: EXPERIMENTAL
Intervention: Venetoclax-obinutuzumab
Number of subjects: 432
Study 31166681 — intervention group
Group type: COMPARATOR
Intervention: Chlorambucil-obinutuzumab
Number of subjects: 432
Study 28095827 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity intervention for smoking cessation during pregnancy
Number of subjects: 0
Study 25293431 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein supplementation (n=18)
Number of subjects: 61
Study 25293431 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy protein supplementation (n=21)
Number of subjects: 61
Study 25293431 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate supplementation (n=22)
Number of subjects: 61
Study 25293431 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall cohort (all groups combined)
Number of subjects: 61
Study 23507474 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy (CBT)
Number of subjects: 17
Study 23507474 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 17
Study 20732932 — intervention group
Group type: EXPERIMENTAL
Intervention: AP-D (pemetrexed 500 mg/m² plus doxorubicin 60 mg/m² every 3 weeks followed by docetaxel 100 mg/m² every 3 weeks)
Number of subjects: 257
Study 20732932 — intervention group
Group type: COMPARATOR
Intervention: AC-D (doxorubicin 60 mg/m² plus cyclophosphamide 600 mg/m² every 3 weeks followed by docetaxel 100 mg/m² every 3 weeks)
Number of subjects: 257
Study 19916712 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular diclofenac sodium at a dose of 2 x 75 mg and additional breakthrough meperidine at 50 mg dosages if necessary
Number of subjects: 130
Study 19916712 — intervention group
Group type: COMPARATOR
Intervention: Meperidine 6 x 50 mg
Number of subjects: 130
Study 17029608 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent pedaling (5 min with 3-min rest intervals at 40 rpm and 0.15 kp load)
Number of subjects: 8
Study 17029608 — intervention group
Group type: COMPARATOR
Intervention: Rest (as control)
Number of subjects: 8
Study 12682802 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin 500 mg four times daily for 7 days
Number of subjects: 14
Study 12682802 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 11052428 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid-filled warming blanket (Group 1, n = 33)
Number of subjects: 101
Study 11052428 — intervention group
Group type: EXPERIMENTAL
Intervention: Heated and humidified breathing circuit (Group 2, n = 31)
Number of subjects: 101
Study 11052428 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous fluid warmers (Group 3, n = 37)
Number of subjects: 101
Study 9261942 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated influenza vaccine (A/Yamagata/32/89, A/Beijing/352/89, B/Bangkok/163/90)
Number of subjects: 0
Study 9261942 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated influenza vaccine (A/Beijing/352/89)
Number of subjects: 0
Study 8000795 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin contents in gastric juice
Number of subjects: 0
Study 8000795 — intervention group
Group type: COMPARATOR
Intervention: Normal subjects
Number of subjects: 0
Study 2883202 — intervention group
Group type: EXPERIMENTAL
Intervention: Astemizole
Number of subjects: 46
Study 2883202 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 31971338 — intervention group
Group type: EXPERIMENTAL
Intervention: IVUS-guided stenting strategy
Number of subjects: 100